Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
about
Trastuzumab cardiotoxicity: from clinical trials to experimental studies.A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
P2860
Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@ast
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@en
type
label
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@ast
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@en
prefLabel
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@ast
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@en
P2093
P1433
P1476
Trastuzumab Emtansine (T-DM1) ...... e T-PAS Expanded Access Study.
@en
P2093
Bongin Yoo
Brian Barnett
Denise A Yardley
Edith A Perez
Ian E Krop
Musa Mayer
Patricia M LoRusso
P304
P356
10.1097/PPO.0000000000000144
P577
2015-09-01T00:00:00Z